Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 31 FCF Margin % is -82.24% as of Mar. 2026. GuruFocus rates BIOE with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 963 Drug Manufacturers companies, Bio Essence ranks better than 98.65% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bio Essence's Free Cash Flow for the
three
months ended in Mar. 2026 was $-0.41 Mil. Bio Essence's Revenue for the
three
months ended in Mar. 2026 was $0.50 Mil. Therefore, Bio Essence's FCF Margin % for the quarter that ended in Mar. 2026 was -82.24%.
The historical rank and industry rank for Bio Essence's FCF Margin % or its related term are showing as below:
BIOE'
s FCF Margin % Range Over the Past 10 Years
Min: -159.12 Med: -94.58 Max: 192.59
Current: 49.83
During the past 7 years, the highest FCF Margin % of Bio Essence was 192.59%. The lowest was -159.12%. And the median was -94.58%.
BIOE's FCF Margin % is ranked better than 98.65% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs BIOE: 49.83
Bio Essence FCF Margin % Related Terms
Bio Essence FCF Margin % Historical Data
* Premium members only.
The historical data trend for Bio Essence's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio Essence's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a FCF Margin % of -82.24% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #13 out of 963 companies in the Drug Manufacturers industry, placing it in the top 1.3%.
Is Bio Essence's FCF Margin % too high?
Bio Essence's current FCF Margin % is -82.24%. Based on the distribution chart, Bio Essence ranks #13 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's FCF Margin % compare to BFRI and APUS?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #13 out of 963 companies for FCF Margin %. This places Bio Essence in the top 1% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current FCF Margin % is -82.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current FCF Margin % of -82.24%. The current FCF Margin % is -82.24%. Bio Essence's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bio Essence (BIOE), the current FCF Margin % is -82.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
31GF Score
Get the complete analysis for BIOE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
